Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 14/20 | 0.67 |
| ▸ | RARG | P13631 | 14/20 | 0.67 |
| ▸ | RARA | P10276 | 11/20 | 0.67 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.67 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.67 |
| ▸ | RXRA | P19793 | 2/20 | 0.52 |
| ▸ | HNF4A | P41235 | 2/20 | 0.52 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.49 |
| ▸ | SSTR5 | P35346 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1320433 | 0.86 | CYP3A4 (0.65) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL7143159 | 0.85 | RARB (0.55) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL2240304 | 0.85 | RARB (0.76) | RARBRARGRARACYP26A1RXRA | |
| SCHEMBL9817651 | 0.84 | RARB (0.53) | RARBRARGRARACYP26A1CYP3A4 | |
| Hydrochloric Acid SCHEMBL9133279 | 0.84 | RARB (0.74) | RARBRARGRARACYP26A1RXRA | |
| SCHEMBL8559730 | 0.83 | RARB (0.54) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL10563217 | 0.83 | RARB (0.70) | RARBRARGRARACYP26A1RXRA | |
| Terephthalic Acid SCHEMBL27259372 | 0.83 | RARB (0.66) | RARBRARGRARACYP26A1RXRA | |
| Terephthalic Acid SCHEMBL27345449 | 0.83 | RARB (0.66) | RARBRARGRARACYP26A1RXRA | |
| SCHEMBL7139314 | 0.83 | RARB (0.52) | RARBRARGRARACYP26A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0290130-B1 | ACETYLENES DISUBSTITUTED WITH A PHENYL GROUP AND A HETEROBICYCLIC GROUP HAVING RETINOID LIKE ACTIVITY | ALLERGAN, INC (US) | 1991-11-06 | — | — | EP | claimed |
| US-4810804-A | PSORIASIS | ALLERGAN, INC. (US) | 1989-03-07 | — | — | US | claimed |
| EP-0290130-A1 | Acetylenes disubstituted with a phenyl group and a heterobicyclic group having retinoid like activity | ALLERGAN, INC (US) | 1988-11-09 | — | — | EP | claimed |
| US-20060030597-A1 | Method of inhibiting angiogenesis | GERRITSEN MARY E | 2006-02-09 | — | — | US | disclosed |
| US-20010036955-A1 | Method of inhibiting angiogenesis | GENENTECH, INC. | 2001-11-01 | — | — | US | disclosed |
| EP-0290130-B1 | ACETYLENES DISUBSTITUTED WITH A PHENYL GROUP AND A HETEROBICYCLIC GROUP HAVING RETINOID LIKE ACTIVITY | ALLERGAN, INC (US) | 1991-11-06 | — | — | EP | disclosed |
| US-4810804-A | PSORIASIS | ALLERGAN, INC. (US) | 1989-03-07 | — | — | US | disclosed |
| EP-0290130-A1 | Acetylenes disubstituted with a phenyl group and a heterobicyclic group having retinoid like activity | ALLERGAN, INC (US) | 1988-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030597-A1 | Method of inhibiting angiogenesis | PPARG, PPARA, RXRG | RARB 13/4885RARG 10/4885RARA 21/4885 |
| US-20010036955-A1 | Method of inhibiting angiogenesis | PPARG, PPARA, RXRG | RARB 13/4885RARG 10/4885RARA 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.